The MitoPark mouse model provides a genetic system that recapitulates key features of sporadic Parkinson's disease through tissue-specific disruption of mitochondrial quality control. This model demonstrates progressive dopaminergic neuron degeneration linked to mitochondrial dysfunction.
| Component |
Details |
| Gene |
Parkin (PARK2) |
| Modification |
Exon 3 floxed (conditional knockout) |
| Cre driver |
DAT-Cre (dopamine transporter promoter) |
| Background |
C57BL/6J |
The model uses Cre-loxP recombination to delete Parkin specifically in dopaminergic neurons:
- Exon 3 deletion: Frameshift mutation, complete loss of function
- DAT-Cre specificity: Targets substantia nigra and VTA dopamine neurons
- Progressive loss: Neuron loss occurs over 12-18 months
Parkin deletion impairs mitophagy:
- PINK1 accumulation: Without Parkin, PINK1 cannot be recruited to damaged mitochondria
- Failed mitophagy: Dysfunctional mitochondria accumulate
- ROS elevation: Damaged mitochondria generate excess reactive oxygen species
- Progressive dysfunction: Mitochondrial defects accumulate over time
- Complex I deficiency: Reduced complex I activity in substantia nigra
- ATP depletion: Progressive energy failure
- Calcium dysregulation: Impaired calcium handling
- Oxidative stress: Elevated lipid peroxidation, protein oxidation
| Age |
Pathology |
Behavioral Impact |
| 3-6 months |
Minimal |
Normal |
| 6-9 months |
Early mitochondrial changes |
Subtle deficits |
| 9-12 months |
Moderate neuron loss |
Clear motor impairment |
| 12-18 months |
Severe degeneration |
Marked parkinsonism |
- Dopaminergic neuron loss: 50-70% loss in substantia nigra by 12 months
- Striatal denervation: Progressive loss of dopaminergic terminals
- Lewy body-like inclusions: Some models show α-synuclein pathology
- Rotarod impairment: Reduced latency to fall
- Cylinder test: Reduced forelimb use
- Pole test: Increased descent time
- Open field: Reduced exploration, increased thigmotaxis
The MitoPark model is ideal for testing:
- Mitochondrial protectants: CoQ10, methylene blue
- Mitophagy enhancers: Urolithin A, rapamycin
- Antioxidants: N-acetylcysteine, vitamin D
- Gene therapy: PARKIN gene delivery
- Mitochondrial dynamics: Fusion/fission imbalance
- Autophagy-lysosome pathway: Role in neuronal survival
- Neuroinflammation: Secondary inflammatory responses
¶ Advantages and Limitations
- Sporadic-like: Model reproduces features of idiopathic PD
- Progressive: Age-dependent degeneration
- Mitochondrial focus: Direct study of mitochondrial pathogenesis
- DAT-Cre specificity: Targeted to relevant neurons
- Complete Parkin loss: More severe than heterozygous PD mutations
- Late onset: Requires aged mice for full phenotype
- Variable penetrance: Background strain effects
- Technical complexity: Requires careful Cre management
- Kitada et al., 2009 - MitoPark mouse model
- Trempe & Fon, 2020 - Parkin function in PD
- McCoy et al., 2016 - MitoPark phenotypic characterization
- Pickrell & Youle, 2015 - The roles of PINK1 and Parkin